Please login to the form below
Krystal Biotech
This page shows the latest Krystal Biotech news and features for those working in and with pharma, biotech and healthcare.
Abeona Therapeutics’ rare disease phase 3 trial halted due to FDA concerns
Following the news, the biotech’s shared dropped more than 20%, as investors became spooked by potential unfavourable results from the pivotal study. ... Krystal Biotech is also developing a candidate for RDEB – KB103 – and reported positive
Latest news
-
Krystal Bio preps pivotal trials for rare skin disease gene therapy
Encouraging results for patients. Krystal Biotech has reported positive results from a mid-stage trial of its gene therapy for a life-threatening rare skin disease, and hopes to start a ... Encouragingly, Krystal’s data is the second piece of
Krystal Bio preps pivotal trials for rare skin disease gene therapy
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Digital strategist
-
Competitive
-
Digital account director
-
Competitive
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Digital project manager
-
Competitive
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- Live Webinar: Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- Another Landmark Lucid Workiversary
- Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- EU approves bluebird bio’s CALD gene therapy Skysona
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- This month in 1939: How dead cattle led to the discovery of warfarin
- Recruiting patients for real-world studies – the power of a digital campaign
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
